Today, the FDA's Vaccines and Related Biological Products Advisory Committee voted 17 to 4 in support of the FDA granting...
Pfizer, BioNTech Receive FDA Advisory Approval for COVID-19 Vaccine Emergency Use in The US

Today, the FDA's Vaccines and Related Biological Products Advisory Committee voted 17 to 4 in support of the FDA granting...
Pfizer announced today the successful conclusion of their mRNA-based BNT162b2 vaccine for SARS-CoV-2 produced in partnership with BioNTech. This news comes shortly after...
Yesterday, Ivanka Trump tweeted the news of 90% efficacy in Pfizer and BioNTech's BNT162 mRNA-based vaccine to combat COVID-19. She then made the bold...
In an annoucement today from Pfizer, the Government of Canada has entered into an agreement with the Pfizer and BioNTech to supply the partnership's BNT162 mRNA-based vaccine to combat COVID-19.
Today Pfizer and BioNTech have jointly announced they are prepared to begin their Phase II/III global trials for their COVID-19 vaccine partnership. Following on review of Phase I/II trial results, the partnership worked with the FDA to select BNT162b2 as the vaccine candidate in the next phases.
In a news release today, the BNT162b1 COVID-19 vaccine under development by Pfizer and BioNTech displayed early positive results in producing neutralizing antibodies from the partnership's Phase I/II trial.